Vaxart Inc
NASDAQ:VXRT 2:27:03 PM EDT
Market Cap (Intraday) | 231.23M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $1.24 |
50-Day MA | $1.14 |
200-Day MA | $0.83 |
Vaxart Inc Stock, NASDAQ:VXRT
170 Harbor Way, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.550.3500
Number of Employees: 125
Description
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.